首页|期刊导航|癌症生物学与医学（英文版）|Glofitamab vs.real-world regimens in Chinese patients with third-or later-line relapsed/refractory diffuse large B-cell lymphoma:an external control study

Glofitamab vs.real-world regimens in Chinese patients with third-or later-line relapsed/refractory diffuse large B-cell lymphoma:an external control study

Keshu Zhou Xiaohui Zhou Yuerong Shuang Huilai Zhang Huijing Wu Xia Zhao Xiaohong Tan Xiaojing Yan Haisheng Liu Liping Su Yukun Lan Jaihui Xu

癌症生物学与医学（英文版）2025，Vol.22Issue(10)：1218-1222,中插12-中插19,13.

癌症生物学与医学（英文版）2025，Vol.22Issue(10)：1218-1222,中插12-中插19,13.DOI:10.20892/j.issn.2095-3941.2025.0104

Glofitamab vs.real-world regimens in Chinese patients with third-or later-line relapsed/refractory diffuse large B-cell lymphoma:an external control study

Keshu Zhou ¹Xiaohui Zhou ²Yuerong Shuang ³Huilai Zhang ⁴Huijing Wu ⁵Xia Zhao ⁶Xiaohong Tan ⁷Xiaojing Yan ⁸Haisheng Liu ⁹Liping Su ¹⁰Yukun Lan ²Jaihui Xu²

作者信息

1. Department of Hematology,Affiliated Cancer Hospital of Zhengzhou University,Henan Cancer Hospital,Zhengzhou 450003,China
2. Shanghai Roche Pharmaceuticals Ltd.,Shanghai 201203,China
3. Department of Lymphatic and Hematological Oncology,Jiangxi Cancer Hospital,Nanchang 330029,China
4. Department of Lymphoma,Tianjin Medical University Cancer Institute and Hospital,Tianjin 300060,China
5. Department of Oncology,Hubei Cancer Hospital,Wuhan 430079,China
6. Department of Lymphoma,The Affiliated Hospital of Qingdao University,Qingdao 266003,China
7. Department of Haematology/Oncology and Paediatric Oncology,Guangxi Medical University Affiliated Cancer Hospital,Nanning 530021,China
8. Department of Hematology,The First Hospital of China Medical University,Shenyang 110001,China
9. Department of Hematology,The Fourth Hospital of Hebei Medical University and Hebei Tumor Hospital,Shijiazhuang 050011,China
10. Department of Hematology,Shanxi Cancer Hospital Institute,Taiyuan 030013,China
折叠

摘要

引用本文复制引用

Keshu Zhou,Xiaohui Zhou,Yuerong Shuang,Huilai Zhang,Huijing Wu,Xia Zhao,Xiaohong Tan,Xiaojing Yan,Haisheng Liu,Liping Su,Yukun Lan,Jaihui Xu..Glofitamab vs.real-world regimens in Chinese patients with third-or later-line relapsed/refractory diffuse large B-cell lymphoma:an external control study[J].癌症生物学与医学（英文版）,2025,22(10):1218-1222,中插12-中插19,13.

基金项目

This study was sponsored by Shanghai Roche Pharmaceuticals Ltd. （）

癌症生物学与医学（英文版）

ISSN：2095-3941

访问量0

下载量0

段落导航